Medicines (MDCO) Investors Overreacting, Says RBC

RBC Capital today maintained an Outperform of The Medicines Company (NASDAQ: MDCO) with a price target of $41.00. Comments follow a claims construction ruling that went against Medicines Co.

Analyst Adnan Butt said the ruling is a modest negative and creates uncertainty over whether Medicines can maintain Angiomax exclusivity. In his view, generic competition in 2015 would lower his price target by $7. However, shares may be overacting given Medicines pipeline. He thinks shares will trade range-bound until further insight and/or trial results with Hospira (NYSE: HSP) scheduled for September.

For an analyst ratings summary and ratings history on The Medicines Company (NASDAQ: MDCO) click here. For more ratings news on The Medicines Company click here.

Shares of The Medicines Company closed at $34.03 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
• Deutsche Bank Upgrades Target Hospitality (TH) to Buy
• Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility